CHAPEL HILL, N.C., Oct. 5 /PRNewswire/ -- While Megabrands are more and more an exception today and many companies invest in specialty therapeutic areas, the underlying principles of how to develop, market, sell and manage a blockbuster drug that will outperform the competition are still the same -- and are still sought after by pharmaceutical and biotech companies alike.
Best Practices, LLC's leading benchmarking report "Launching Pharmaceutical Megabrands: Best Practices in Marketing Blockbusters" delivers the critical building blocks essential for new product management pre and post launch. What separates industry leaders from other pharmaceutical executives is vital knowledge of when in the process to start building and where to focus resources during development - the report provides those answers.
For a complimentary download of research study excerpts, please visit http://www3.best-in-class.com/rr862.htm.
In the benchmarking report, research analysts compile compelling metrics, best practices and lessons learned from survey responses and in-depth interviews with 24 top executives at companies such as Pfizer, Merck, Sanofi-Aventis, GlaxoSmithKline, Eli Lilly, Amgen, Boehringer-Ingelheim and Novartis.
The myriad of insights gleaned from interviewees on such topics as marketing support investment and expense patterns for high potential products will inform all marketing and branding decision-makers throughout the drug development cycle.
To learn more about the winning tactics, proven investment patterns and other tried-and-true strategies for optimizing drug launch success, see the complimentary report summary at http://www3.best-in-class.com/rr862.htm.
To drill down on the countless metrics and best practices presented in
this report contact our Solution Specialists at (919) 403-0251 o
|SOURCE Best Practices, LLC|
Copyright©2007 PR Newswire.
All rights reserved